Patents
Literature
3 results about "Beta-peptide" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Β-peptides consist of β amino acids, which have their amino group bonded to the β carbon rather than the α carbon as in the 20 standard biological amino acids. The only common naturally occurring β amino acid is β-alanine; although it is used as a component of larger bioactive molecules, β-peptides in general do not appear in nature. For this reason β-peptide-based antibiotics are being explored as ways of evading antibiotic resistance. Early studies in this field were published in 1996 by the group of Dieter Seebach and that of Samuel Gellman.
MULTITARGET CHIMERIC ANTIGEN FOR ALZHEIMER'S DISEASE IMMUNOTHERAPY
The present invention relates to the biomedical and biopharmaceutical sectors. Specifically, it relates to a chimeric antigen comprising the combination of the amino- and carboxy-terminal regions of the amyloid-beta peptide (Aβ), the amino- and carboxy-terminal regions of the tau protein, and a T-cell epitope. The pharmaceutical composition comprising this chimeric antigen and at least one pharmaceutically acceptable vaccine adjuvant increases the efficacy of immunotherapy for the prevention and treatment of Alzheimer's disease (AD). The chimeric antigen exerts its action by stimulating a multi-target humoral response with high titers of anti-Aβ and anti-tau antibodies simultaneously. This promotes the combined elimination of toxic Aβ and tau species from the brain, thereby preventing or significantly improving the clinical symptoms and neuropathology of AD.
Owner:CENT DE ING GENETICA & BIOTECNOLOGIA +1
Anti-N3pGlu amyloid-beta peptide antibody and its use
To provide a method of treating or preventing a disease characterized by deposition of Aβ in a brain, including Alzheimer's disease (AD), Down's syndrome, and cerebral amyloid angiopathy (CAA).SOLUTION: A method of treating or preventing a disease characterized by amyloid beta (Aβ) deposits in the brain of a patient comprises administering to the patient an induction dose of 10 to 60 mg / kg of an anti-N3pGlu Aβ antibody for a period of 6 months or less.SELECTED DRAWING: None
Owner:ELI LILLY & CO